MDLN vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MDLN exhibits strong fundamental health with a Piotroski F-Score of 7/9 and exceptional liquidity (Current Ratio 4.29), suggesting a stable operational baseline. However, the stock is currently trading at a premium to its Intrinsic Value ($42.18) and significantly above its Graham Number ($20.63). This valuation gap, combined with a starkly bearish technical trend and massive insider liquidation exceeding $3.5 billion, offsets the positive analyst consensus and revenue growth.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
MDLN vs MRK: Head-to-Head Comparison
This page compares Medline Inc. (MDLN) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.